Many functions of the chaperone, heat shock protein 90 (hsp90), are inhibited by the drug geldanamycin that specifically binds hsp90. We have studied an amino-terminal domain of hsp90 whose crystal structure has recently been solved and determined to contain a geldanamycin-binding site. We demonstrate that, in solution, drug binding is exclusive to this domain. This domain also binds ATP linked to Sepharose through the ␥-phosphate. Binding is specific for ATP and ADP and is inhibited by geldanamycin. Mutation of four glycine residues within two proposed ATP binding motifs diminishes both geldanamycin binding and the ATP-dependent conversion of hsp90 to a conformation capable of binding the co-chaperone p23. Since p23 binding requires regions outside the 1-221 domain of hsp90, these results indicate a common site for nucleotides and geldanamycin that regulates the conformation of other hsp90 domains.Heat shock protein 90 (hsp90) 1 is a cellular chaperone that participates in multiple signal transduction pathways. Recent studies have demonstrated a requirement for hsp90, or grp94, its homolog in the endoplasmic reticulum, for the proper function of 1) the mitogen-activated protein kinase pathway (1-6); 2) activity of several tyrosine kinases (Refs. 7-9 and references therein); 3) activity of several transcription factors, including p53 (10), retinoid receptors (11), steroid and aryl hydrocarbon receptors (Refs. 12 and 13 and references therein), and hypoxia-inducible factor ␣ (14); 4) activity of the cyclin-dependent kinase CDK4 (15) and the cell cycle-associated Wee1 tyrosine kinase (16); and even 5) activity of hepatitis B virus reverse transcriptase (17). Additionally, hsp90 has been shown to participate in the refolding of certain misfolded proteins (18 -20). hsp90 comprises the core of several multi-molecular chaperone complexes that interact with proteins at different stages of their maturation. The ability of hsp90 to participate in the assembly of multiple higher order chaperone complexes no doubt contributes to its involvement in diverse cellular pathways, although those factors regulating such participation remain unclear.Until recently, yeast in which hsp90 is either mutated or conditionally suppressed has served as the only means by which to study the many functions of this chaperone in the cell. The recent observation that a class of drugs known as benzoquinone ansamycins, including herbimycin A and geldanamycin (GA), specifically bind and inhibit hsp90 and grp94 has provided a new tool for functional studies of these chaperones (9, 21). Indeed, a study of structure-activity relationships has demonstrated a high correlation between the biologic effects of the benzoquinone ansamycins and their ability to bind hsp90 (22). These drugs have also been shown to possess anti-tumor activity in preclinical models, identifying the hsp90 chaperone family as a novel target for anticancer drug development (23).For these reasons, it is of much interest to characterize the drug binding site in hsp90, both to underst...
The chaperone hsp90 is capable of binding and hydrolyzing ATP. Using information on a related ATPase, DNA gyrase B, we selected three conserved residues in hsp90's ATP-binding domain for mutation. Two of these mutations eliminate nucleotide binding, while the third retains nucleotide binding but is apparently deficient in ATP hydrolysis. We first analyzed how these mutations affect hsp90's binding to the co-chaperones p23 and Hop, and to the hydrophobic resin, phenyl-Sepharose. These experiments showed that ATP's effects, specifically, increased affinity for p23 and decreased affinity for Hop and phenyl-Sepharose, are brought on by ATP binding alone. We also tested the ability of hsp90 mutants to assist hsp70, hsp40, and Hop in the refolding of denatured firefly luciferase. While hsp90 is capable of participating in this process in a nucleotide-independent manner, the ability to hydrolyze ATP markedly potentiates hsp90's effect. Finally, we assembled progesterone receptor heterocomplexes with hsp70, hsp40, Hop, p23, and wild type or mutant hsp90. While neither ATP binding nor hydrolysis was necessary to bind hsp90 to the receptor, mature complexes containing p23 and capable of hormone binding were only obtained with wild type hsp90.The 90-kDa heat shock protein (hsp90) 1 is an abundant and highly conserved protein involved in a diverse array of cellular processes. Its fundamental importance is underscored by its presence in all species studied, from Escherichia coli to humans, with a remarkable 40% amino acid identity (1, 2). Additionally, the level of hsp90 expressed in various human and murine tissues represents up to 2% of total protein (3), and deletion studies in yeast have shown that hsp90 is essential for viability (4). The common thread in many of its known activities is the chaperoning of substrate proteins to activate their function. This has been most extensively studied with steroid receptors, where hsp90 is required to fold the hormone-binding domain of these receptors into a conformation with high affinity for steroid (see Ref. 5 for a review). In this process, hsp90 acts in protein heterocomplexes with a number of other proteins, including hsp70, hsp40, and the co-chaperones Hop and p23 (6 -8). Heterocomplex formation as well as hsp90/co-chaperone interaction are known to be nucleotide-regulated (9 -11). Hsp90 also participates in a more general protein folding process with hsp70, hsp40, and Hop which requires nucleotides (9, 12), and it can hold and stabilize denatured proteins for subsequent refolding by hsp70/hsp40 (13) or GroEL/ES (14). On its own, hsp90 can bind proteins (15-19), peptides (18,19), and hydrophobic resins (11,20,21), but the effect of nucleotides on these activities is variable and may depend upon the substrate involved.Recently, clear evidence in the form of biochemical (22-24) and crystallographic (25) studies has been presented demonstrating nucleotide binding to hsp90. This binding occurs in the NH 2 -terminal domain of hsp90 at the same site as geldanamycin binding (22,25,...
Background. Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neurooncology patients. Methods. We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes. Results. Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor. In 25 cases (81%), results impacted patient management by: (i) clarifying diagnosis, (ii) identifying pathogenic germline mutations, or (iii) detecting potentially targetable alterations. The pathologic diagnosis was amended after genomic profiling for 6 patients (19%), including a high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to CNS high-grade neuroepithelial tumor with BCOR alteration. Multiple patients had pathogenic germline mutations, many of which were previously unsuspected. Potentially targetable alterations were identified in 19 patients (61%). Additionally, novel likely pathogenic alterations were identified in 3 cases: an in-frame RAF1 fusion in a BRAF wild-type pleomorphic xanthoastrocytoma, an inactivating ASXL1 mutation in a histone H3
Matrix rigidity has important effects on cell behavior and is increased during liver fibrosis; however, its effect on primary hepatocyte function is unknown. We hypothesized that increased matrix rigidity in fibrotic livers would activate mechanotransduction in hepatocytes and lead to inhibition of hepatic-specific functions. To determine the physiologically relevant ranges of matrix stiffness at the cellular level, we performed detailed atomic force microscopy analysis across liver lobules from normal and fibrotic livers. We determined that normal liver matrix stiffness was around 150Pa and increased to 1–6kPa in areas near fibrillar collagen deposition in fibrotic livers. In vitro culture of primary hepatocytes on collagen matrix of tunable rigidity demonstrated that fibrotic levels of matrix stiffness had profound effects on cytoskeletal tension and significantly inhibited hepatocyte-specific functions. Normal liver stiffness maintained functional gene regulation by hepatocyte nuclear factor 4 alpha (HNF4α) whereas fibrotic matrix stiffness inhibited the HNF4α transcriptional network. Fibrotic levels of matrix stiffness activated mechanotransduction in primary hepatocytes through focal adhesion kinase (FAK). In addition, blockade of the Rho/Rho-associated protein kinase (ROCK) pathway rescued HNF4α expression from hepatocytes cultured on stiff matrix. Conclusion Fibrotic levels of matrix stiffness significantly inhibit hepatocyte-specific functions in part by inhibiting the HNF4α transcriptional network mediated through the Rho/ROCK pathway. Increased appreciation of the role of matrix rigidity in modulating hepatocyte function will advance our understanding of the mechanisms of hepatocyte dysfunction in liver cirrhosis and spur development of novel treatments for chronic liver disease.
Ganglioglioma is the most common epilepsy-associated neoplasm that accounts for approximately 2% of all primary brain tumors. While a subset of gangliogliomas are known to harbor the activating p.V600E mutation in the BRAF oncogene, the genetic alterations responsible for the remainder are largely unknown, as is the spectrum of any additional cooperating gene mutations or copy number alterations. We performed targeted next-generation sequencing that provides comprehensive assessment of mutations, gene fusions, and copy number alterations on a cohort of 40 gangliogliomas. Thirty-six harbored mutations predicted to activate the MAP kinase signaling pathway, including 18 with BRAF p.V600E mutation, 5 with variant BRAF mutation (including 4 cases with novel in-frame insertions at p.R506 in the β3-αC loop of the kinase domain), 4 with BRAF fusion, 2 with KRAS mutation, 1 with RAF1 fusion, 1 with biallelic NF1 mutation, and 5 with FGFR1/2 alterations. Three gangliogliomas with BRAF p.V600E mutation had concurrent CDKN2A homozygous deletion and one additionally harbored a subclonal mutation in PTEN. Otherwise, no additional pathogenic mutations, fusions, amplifications, or deletions were identified in any of the other tumors. Amongst the 4 gangliogliomas without canonical MAP kinase pathway alterations identified, one epilepsy-associated tumor in the temporal lobe of a young child was found to harbor a novel ABL2-GAB2 gene fusion. The underlying genetic alterations did not show significant association with patient age or disease progression/recurrence in this cohort. Together, this study highlights that ganglioglioma is characterized by genetic alterations that activate the MAP kinase pathway, with only a small subset of cases that harbor additional pathogenic alterations such as CDKN2A deletion.Electronic supplementary materialThe online version of this article (10.1186/s40478-018-0551-z) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.